Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders

Psychosomatic Medicine

Volumn 65, Issue 1, 2003, Pages 156-162

  Dolder, Christian R ^a,b   Lacro, Jonathan P ^a,b   Jeste, Dilip V ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Diabetes; Hyperlipidemia; Hypertension; Medication adherence; Psychosis

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SCHIZOPHRENIA; SOCIOECONOMICS;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICAL RECORDS; MIDDLE AGED; OUTPATIENTS; PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG; PSYCHOTIC DISORDERS; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0037252431     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PSY.0000040951.22044.59     Document Type: Article

References (61)

1. Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia: implications for the post-institutional era in the US. Pharmacoeconomics 1995;8:199-222.
2. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29.
3. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-51.
4. Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP. Medical comorbidity in schizophrenia. Schizophr Bull 1996;22:413-30.
5. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999;60(Suppl 21):10-5.
6. Koranyi EK. Somatic illness in psychiatric patients. Psychosomatics 1980;21:887-91.
7. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49: 196-201.
8. Schwed A, Fallab CL, Burnier M, Waeber B, Kappenberger L, Burnand B, Darioli R. Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J Clin Pharmacol 1999;39:402-9.
9. Shobhana R, Begum R, Snehalatha C, Vijay V, Ramachandran A. Patients' adherence to diabetes treatment. J Assoc Physicians India 1999;47:1173-5.
10. Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Lancet 1997;350: 1505-10.
11. Lee JY, Kusek JW, Greene PG, Bernhard S, Norris K, Smith D, Wilkening B, Wright JT. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension. Am J Hypertens 1996;9: 719-25.
12. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
13. Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Med Care 2001;3:846-57.
14. Blumenfeld JD. Renal and cardiac complications of hypertension. Clin Symp 1994;46:3-32.
15. Froom J, Froom P, Benjamin M, Benjamin BJ. Measurement and management of hyperlipidemia for the primary prevention of coronary heart disease. J Am Board Fam Pract 1998;11:12-22.
16. Nicolucci A, Cavaliere D, Scorpiglione N, Carinci F, Capani F, Tognoni G, Benedetti MM. A comprehensive assessment of the avoidability of long-term complications of diabetes: a case-control study. Diabetes Care 2001;19:927-33.
17. Allebeck P, Wistedt B. Mortality in schizophrenia. Arch Gen Psychiatry 1986;43:650-3.
18. Koranyi EK. Morbidity and rate of undiagnosed physical illnesses in a psychiatric clinic population. Arch Gen Psychiatry 1979;36:414-9.
19. Tsuang MT, Perkins K, Simpson JC. Physical diseases in schizophrenia and affective disorder. J Clin Psychiatry 1983;44:42-6.
20. Deleted in proof.
21. Salzman C. Medication compliance in the elderly. J Clin Psychiatry 1995;56(Suppl 1):18-22.
22. Arean PA. Cognitive behavioral therapy with older adults. Behav Ther 1993;17:236-9.
23. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. Can Med Assoc J 1999;160:31-7.
24. Rosenstock IM. Enhancing patients compliance with health recommendations. J Pediatr Health Care 1988;2:67-72.
25. Sackett D, Haynes R, Gibson E, Taylor D, Roberts R, Johnson A. Patient compliance with antihypertensive regimens. Patient Counseling Health Educ 1978;1:18-21.
26. Bloom BS. Continuation of initial antihypertensive medications after 1 year of therapy. Clin Ther 1998;20:1-11.
27. Eraker S, Kirscht J, Becker M. Understanding and improving patient compliance. Ann Intern Med 1994;100:258-68.
28. Mallion J, Baguet J, Siche J, Tremel F, De Gaudemaris R. Compliance, electronic monitoring and antihypertensive drugs. J Hypertens 1998;16(Suppl 1):S75-9.
29. Shepherd J. Tomorrow's world: atherosclerosis in the year 2000. Neth J Med 1997;50:221-7.
30. Sung JCY, Nichol MB, Venturini F, Bailey KL, McCombs JS, Cody M. Factors affecting patient compliance with antihyperlipidemic medications in a HMO population. Am J Managed Care 1998;4:1421-30.
31. Dolder CR, Lacro JP, Jeste DV. Medication adherence: is there a difference between typical and atypical antipsychotics? Am J Psychiatry 2002;159:103-8.
32. Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, Henderson W, Charney D. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000;61:382-6.
33. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000; 51:216-22.
34. Fleischhacker WW. Clozapine: a comparison with other novel antipsychotics. J Clin Psychiatry 1999;60(Suppl 12):30-4.
35. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-55.
36. Purdon SE. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res 1999;35:S51-60.
37. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999;46:1396-408.
38. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16.
39. Hamilton RA, Briceland LL. Use of prescription-refill records to assess patient compliance. Am J Hosp Pharm 1992;49:1691-6.
40. Duncan JC, Rogers R. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders. J Forensic Sci 1998;43:1133-7.
41. Agarwal MR, Sharma VK, Kumar K, Lowe D. Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatry 1998;44:92-106.
42. Buchanan RW, Kirkpatrick B, Summerfelt A, Hanlon TE, Levine J, Carpenter WT Jr. Clinical predictors of relapse following neuroleptic withdrawal. Biol Psychiatry 1992;32:72-8.
43. Grunebaum MF, Weiden PJ, Olfson M. Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study. J Clin Psychiatry 2001;62:394-9.
44. Nageotte C, Sullivan G, Duan N, Camp PL. Medication compliance among the seriously mentally ill in a public mental health system. Soc Psychiatry Psychiatr Epidemiol 1997;32:49-56.
45. Pan PC, Tantam D. Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic. Acta Psychiatr Scand 1989;79:564-70.
46. Murray MD, Darnell I, Weinberger M, Martz BL. Factors contributing to medication noncompliance in elderly public housing tenants. Drug Intell Clin Pharm 1986;20:146-52.
47. Burris JF, Papademetriou V, Wallin JD, Cook ME, Weidler DJ. Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension. Am J Med 1999;91:22S-8S.
48. Feldman R, Bacher M, Campbell N, Drover A, Chockalingam A. Adherence to pharmacologic management of hypertension. Can J Public Health 1998;89:116-8.
49. Svensson S, Kjellgren KI, Ahlner J, Saljo R. Reasons for adherence with antihypertensive medication. Int J Cardiol 2000;76:157-63.
50. Mansur AP, Mattar AP, Tsubo CE, Simao DT, Yoshi FR, Daci K. Prescription and adherence to statins of patients with coronary artery disease and hypercholesterolemia. Arq Bras Cardiol 2001;76:111-8.
51. Kelly GR. Utility of the health belief model in examining medication compliance among psychiatric outpatients. Soc Sci Med 1987;25:1205-11.
52. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60(Suppl 21):25-30.
53. Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, Frances A. Rating of Medication Influences (ROMI) Scale in schizophrenia. Schizophr Bull 1994;20:297-310.
54. Janz NK, Becker MH. The health belief model: a decade later. Health Educ Q 1984;11:1-47.
55. Larosa JH, Larosa JC. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med 2001;9:1169-75.
56. Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA. Measuring adherence to behavioral and medical interventions. Controlled Clin Trials 2000;21:188S-94S.
57. Deyo RA, Inui TS, Sullivan B. Noncompliance with arthritis drugs: magnitude, correlates, and clinical implications. J Rheumatol 1981;8:931-6.
58. Peterson GM, McLean S, Millingen KS. Determinants of patient compliance with anticonvulsant therapy. Epilepsia 1982;23: 607-13.
59. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Med Care 1988;26:814-23.
60. Steiner JF, Fihn SD, Blair B, Inui TS. Appropriate reductions in compliance among well-controlled hypertensive patients. J Clin Epidemiol 1991;44:1361-71.
61. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Canning C, Platt R. Validations of patients reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999;37:846-57.